Skip to content


BMC Proceedings

Open Access

JAKs and STATs in chemoresistance

BMC Proceedings20104(Suppl 2):O15

Published: 24 September 2010


Immune ResponseCancer PatientSignal TransducerDrug ResistanceTherapeutic Strategy

Many cancer patients develop resistance to chemotherapeutic drugs and this results in elevated mortality. Understanding the mechanisms that mediate drug resistance is critical to develop novel therapeutic strategies. Fibroblast growth factor (FGF)-2, which leads to the formation of a B-RAF/PKCε/S6K2 multi-protein complex, plays a key role in chemoresistance. This enhances the selective translation of anti-apoptotic proteins such as BCL-2 and IAP family members and protects cells from death induced by chemotherapy in several cancer types. We have been investigating the role of Janus kinases (JAKs) and signal transducers and activators of transcription (STATs), most notably known for their pivotal roles in mediating cytokine and immune responses, in FGF-2-mediated chemoresistance. The participation of JAKs in drug resistance pathways and the implications of using inhibitors to these kinases in cancer multi-target therapies will be discussed.

Authors’ Affiliations

Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK


© Costa-Pereira; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.